Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultrarare diseases, has announced the grant of 19,875 restricted stock units to 14 newly hired non-executive officers. The awards, approved by the company's compensation committee, were granted under the Ultragenyx Employment Inducement Plan on July 16, 2024. This move aligns with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for new employees joining Ultragenyx.
The restricted stock units have a four-year vesting period, with 25% of the underlying shares vesting annually on the grant date anniversary. Continuous employment with Ultragenyx is required for vesting. This grant demonstrates the company's commitment to attracting and retaining talent in the competitive biopharmaceutical industry.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), un'azienda biofarmaceutica specializzata in malattie rare e ultrarare, ha annunciato la concessione di 19.875 unità di azioni riservate a 14 nuovi funzionari non esecutivi. I premi, approvati dal comitato di compensazione dell'azienda, sono stati concessi nell'ambito del Piano di Induzione all'Occupazione di Ultragenyx il 16 luglio 2024. Questa mossa è in linea con la Regola di Iscrizione Nasdaq 5635(c)(4), servendo da incentivo per i nuovi dipendenti che si uniscono a Ultragenyx.
Le unità di azioni riservate hanno un periodo di maturazione di quattro anni, con il 25% delle azioni sottostanti che maturano annualmente nell'anniversario della concessione. È richiesta la continuazione dell'impiego con Ultragenyx per la maturazione. Questa concessione dimostra l'impegno dell'azienda ad attrarre e trattenere talenti nell'industria biofarmaceutica competitiva.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una compañía biofarmacéutica especializada en enfermedades raras y ultrarraras, ha anunciado la concesión de 19.875 unidades de acciones restringidas a 14 nuevos oficiales no ejecutivos. Los premios, aprobados por el comité de compensación de la compañía, se concedieron bajo el Plan de Inducción al Empleo de Ultragenyx el 16 de julio de 2024. Este movimiento está alineado con la Regla de Listado Nasdaq 5635(c)(4), sirviendo como un incentivo para los nuevos empleados que se unen a Ultragenyx.
Las unidades de acciones restringidas tienen un período de consolidación de cuatro años, con el 25% de las acciones subyacentes consolidándose anualmente en el aniversario de la concesión. Se requiere empleo continuo con Ultragenyx para la consolidación. Esta concesión demuestra el compromiso de la empresa de atraer y retener talento en la competitiva industria biofarmacéutica.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)는 희귀 및 초희귀 질환을 전문으로 하는 생물 제약 회사로, 14명의 신규 비임원에게 19,875개의 제한 주식 단위를 수여한다고 발표했습니다. 이 상은 회사의 보상위원회에 의해 승인되었으며, Ultragenyx 고용 유도 계획에 따라 2024년 7월 16일에 부여되었습니다. 이 조치는 Nasdaq 상장 규정 5635(c)(4)와 일치하며, Ultragenyx에 합류하는 신규 직원에 대한 유인책으로 작용합니다.
제한 주식 단위는 4년의 베스팅 기간을 가지며, 기초 주식의 25%가 부여일 기념일마다 매년 베스트됩니다. 베스팅을 위해서는 Ultragenyx와의 지속적인 고용이 필요합니다. 이 보상은 경쟁이 치열한 생물 제약 산업에서 인재를 유치하고 유지하려는 회사의 의지를 보여줍니다.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), une entreprise biopharmaceutique spécialisée dans les maladies rares et ultraraires, a annoncé la concession de 19 875 unités d'actions restrictives à 14 nouveaux dirigeants non exécutifs. Les récompenses, approuvées par le comité de rémunération de l'entreprise, ont été accordées dans le cadre du Plan d'incitation à l'emploi d'Ultragenyx le 16 juillet 2024. Cette initiative est en accord avec la Règle d'inscription Nasdaq 5635(c)(4), servant d'incitation pour les nouveaux employés rejoignant Ultragenyx.
Les unités d'actions restrictives ont une période d'acquisition de quatre ans, avec 25 % des actions sous-jacentes acquises annuellement à l'anniversaire de la date d'attribution. Un emploi continu chez Ultragenyx est requis pour l'acquisition. Cette attribution démontre l'engagement de l'entreprise à attirer et à retenir des talents dans l'industrie biopharmaceutique compétitive.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf seltene und ultrarare Krankheiten spezialisiert hat, hat die Gewährung von 19.875 eingeschränkten Aktieneinheiten an 14 neu eingestellte Nicht-Management-Direktoren bekannt gegeben. Die Auszeichnungen, die vom Vergütungsausschuss des Unternehmens genehmigt wurden, wurden im Rahmen des Ultragenyx Employment Inducement Plans am 16. Juli 2024 vergeben. Dieser Schritt entspricht der Nasdaq-Listing-Regel 5635(c)(4) und dient als Anreiz für neue Mitarbeiter, die zu Ultragenyx stoßen.
Die eingeschränkten Aktieneinheiten haben eine vierjährige Vestingperiode, wobei 25% der zugrunde liegenden Aktien jährlich am Jahrestag des Gewährungsdatums vesten. Eine kontinuierliche Beschäftigung bei Ultragenyx ist für das Vesting erforderlich. Diese Gewährung zeigt das Engagement des Unternehmens, Talente in der wettbewerbsintensiven biopharmazeutischen Branche zu gewinnen und zu halten.
- Ultragenyx is actively recruiting new talent, indicating potential company growth
- The company is using stock-based compensation to align employee interests with shareholders
- None.
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 19,875 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
How many restricted stock units did Ultragenyx (RARE) grant to new employees on July 16, 2024?
What is the vesting schedule for the restricted stock units granted by Ultragenyx (RARE)?
Under which plan were the restricted stock units granted by Ultragenyx (RARE)?
What is Ultragenyx Pharmaceutical Inc. (RARE) focused on developing?
